Category: News

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018

February 12, 2019

Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and…

Read More

BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast

February 5, 2019

Bergen, Norway, 05 February 2019 - BerGenBio ASA (OSE:BGBIO), will announce its results for the…

Read More

BerGenBio announces start of phase I trial evaluating ADCT-601, a novel anti-AXL ADC, in patients with advanced solid tumours

January 21, 2019

ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for…

Read More

BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149

January 9, 2019

BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio’s…

Read More

BerGenBio to present company overview at Biotech Showcase 2019 during annual J.P. Morgan Conference in San Francisco

January 8, 2019

Bergen, Norway, Jan 8th 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on…

Read More

BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS

January 4, 2019

Phase II monotherapy study of bemcentinib in high-risk MDS & AML Will enrol up to…

Read More